Matteo Lambertini, Lucia Del Mastro, Andrea Bellodi, P. Pronzato,
Granulocyte-colony stimulating factors (G-CSFs) are commonly employed in clinical practice. The most relevant adverse event of G-CSF administration is bone pain. Approximately 20% of cancer patients experienced bone pain with the administration of prophylactic daily G-CSFs (lenograstim and filgrastim). The reported incidence of bone pain in cancer patients undergoing pegfilgrastim prophylaxis ranged from 25% to 38%. In healthy donors the incidence of bone pain was higher than in cancer patients, ranging ...
Tópico(s): Leprosy Research and Treatment
2013 - Elsevier BV | Critical Reviews in Oncology/Hematology
Matteo Lambertini, Lucia Del Mastro, M. Pescio, Claus Yding Andersen, Hatem A. Azim, Fedro A. Peccatori, Mauro Costa, Alberto Revelli, Francesca Salvagno, Alessandra Gennari, Filippo Maria Ubaldi, Giovanni Battista La Sala, Cristofaro De Stefano, William H. Wallace, Ann H. Partridge, Paola Anserini,
In the last years, thanks to the improvement in the prognosis of cancer patients, a growing attention has been given to the fertility issues. International guidelines on fertility preservation in cancer patients recommend that physicians discuss, as early as possible, with all patients of reproductive age their risk of infertility from the disease and/or treatment and their interest in having children after cancer, and help with informed fertility preservation decisions. As recommended by the American ...
Tópico(s): Assisted Reproductive Technology and Twin Pregnancy
2016 - BioMed Central | BMC Medicine
Matteo Lambertini, Lucia Del Mastro, Giulia Viglietti, Noam Pondé, Cinzia Solinas, Evandro de Azambuja,
Tópico(s): Estrogen and related hormone effects
2017 - Springer Science+Business Media | Current Treatment Options in Oncology
Benedetta Conte, Alessandra Fabi, Francesca Poggio, Eva Blondeaux, Chiara Dellepiane, Alessia D’Alonzo, Giuseppe Buono, Grazia Arpino, Valentina Magri, Giuseppe Naso, Daniele Presti, Silvia Mura, Andrea Fontana, Francesco Cognetti, Chiara Molinelli, Simona Pastorino, Claudia Bighin, Loredana Miglietta, Francesco Boccardo, Matteo Lambertini, Lucia Del Mastro,
Background T-DM1 improves progression-free survival (PFS) and overall survival (OS) in patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer progressing on prior trastuzumab plus a taxane. A paucity of data is available on T-DM1 efficacy after dual anti-HER2 blockade with pertuzumab and trastuzumab plus a taxane, which represents the current first-line standard of care. The present study is a retrospective/prospective evaluation of the efficacy and activity ...
Tópico(s): Peptidase Inhibition and Analysis
2019 - Elsevier BV | Clinical Breast Cancer
M. Condorelli, Matteo Lambertini, Lucia Del Mastro, Francesco Boccardo, Isabelle Demeestere, Sharon L. Bober,
Purpose of review To provide an up-to-date overview on indications, efficacy and safety of the existing fertility preservation strategies as well as on the features and management of sexual dysfunction in young adult women with newly diagnosed cancer. Recent findings Because of the improved life expectancy of cancer survivors, a growing attention should be given to the side effects of anticancer treatments. Among young cancer patients, risk of infertility and sexual dysfunction are of great concern. ...
Tópico(s): Male Breast Health Studies
2019 - Lippincott Williams & Wilkins | Current Opinion in Oncology
Elisa Toto, Lucia Lambertini, Susanna Laurenzi, M. Gabriella Santonicola,
Space exploration requires the use of suitable materials to protect astronauts and structures from the hazardous effects of radiation, in particular, ionizing radiation, which is ubiquitous in the hostile space environment. In this scenario, polymer-based materials and composites play a crucial role in achieving effective radiation shielding while providing low-weight and tailored mechanical properties to spacecraft components. This work provides an overview of the latest developments and challenges ...
Tópico(s): Radiation Effects in Electronics
2024 - Multidisciplinary Digital Publishing Institute | Polymers
Francesco Cognetti, Paolo Bruzzi, Sabino De Placido, Michelino De Laurentiis, C. Boni, Enrico Aitini, Antonio Durando, Anna Turletti, Elena del Valle, Ornella Garrone, Fabio Puglisi, Filippo Montemurro, Sandro Barni, Benedetto Di Blasio, Teresa Gamucci, Giuseppe Colantuoni, N. Olmeo, Carlo Tondini, A Parisi, Claudia Bighin, S. Pastorino, Matteo Lambertini, Lucia Del Mastro,
Abstract Background. Using a 2 × 2 factorial design, we compared the efficacy of two different schedules of chemotherapy (CT), dose-dense (DD) every 2 weeks versus standard duration every 3 weeks and the role of Fluorouracil (F) in addition to EC, in the adjuvant treatment of node positive BC pts. Patients and Methods. Node positive early BC pts younger than 70 years were eligible and randomly assigned to one of the following treatment arms: ARM A (4 courses of EC [90/600 mg/m2, on day 1, q 21] followed ...
Tópico(s): Breast Lesions and Carcinomas
2013 - American Association for Cancer Research | Cancer Research
Matteo Lambertini, Lucia Del Mastro, G. Gardin, Alessia Levaggi, Claudia Bighin, S. Giraudi, P. Pronzato,
Drug reactions resulting from chemotherapy agents are common and frequently affect the skin. Although often benign, a select few of these cutaneous reactions may necessitate immediate changes to the antineoplastic regimens. Given the diversity of chemotherapeutic skin reactions and their complex implications on patient management, an organized conceptual schema is imperative for proper patient care. We evaluate a number of commonly seen chemotherapy-induced skin toxicities organized by pathogenic ...
Tópico(s): Lymphoma Diagnosis and Treatment
2012 - Elsevier BV | Leukemia Research
Eva Blondeaux, Arlindo R. Ferreira, Francesca Poggio, Fabio Puglisi, Claudia Bighin, Federico Sottotetti, Filippo Montemurro, Elena Poletto, Antonella Lai, Valentina Sini, Gabriele Minuti, Silvia Mura, Andrea Fontana, Piero Fregatti, Bárbara Cardinali, Matteo Lambertini, Lucia Del Mastro,
BackgroundIn the prepertuzumab era, we evaluated the clinical outcomes of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who underwent first-line trastuzumab-based or lapatinib-based therapy according to prior exposure to (neo)adjuvant trastuzumab.Materials and methodsIn this multicentre retrospective cohort study conducted in 14 Italian centres of the Gruppo Italiano Mammella, consecutive patients undergoing first-line trastuzumab or lapatinib-based ...
Tópico(s): Chronic Myeloid Leukemia Treatments
2020 - Elsevier BV | ESMO Open
Matteo Lambertini, Luigi Santoro, Lucia Del Mastro, Bastien Nguyen, Luca Livraghi, Donatella Ugolini, Fedro A. Peccatori, Hatem A. Azim,
Abstract Background Breast cancer is composed of distinct subtypes defined mainly based on the expression of hormone receptors (HR) and HER2. For years, reproductive factors were shown to impact breast cancer risk but it is unclear whether this differs according to tumor subtype. In this meta-analysis we evaluated the association between parity, age at first birth, breastfeeding and the risk of developing breast cancer according to tumor subtype. Methods PubMed and Embase were searched to identify epidemiological ...
Tópico(s): Epigenetics and DNA Methylation
2016 - Elsevier BV | Cancer Treatment Reviews
Claudia Massarotti, Paola Scaruffi, Matteo Lambertini, Valentino Remorgida, Lucia Del Mastro, Paola Anserini,
Tópico(s): Ovarian function and disorders
2017 - Elsevier BV | Cancer Treatment Reviews
Matteo Lambertini, Florence Horicks, Lucia Del Mastro, Ann H. Partridge, Isabelle Demeestere,
Tópico(s): Ovarian cancer diagnosis and treatment
2018 - Elsevier BV | Cancer Treatment Reviews
Matteo Lambertini, Francesca Poggio, Alessia Levaggi, Lucia Del Mastro,
Lambertini, Matteo MD; Poggio, Francesca MD; Levaggi, Alessia MD; Del Mastro, Lucia MD Author Information
Tópico(s): Ovarian function and disorders
2015 - Lippincott Williams & Wilkins | Obstetrics and Gynecology
Carmine Valenza, Dario Trapani, Sara Gandini, Caterina Sposetti, Luca Boscolo Bielo, Antonio Marra, Tommaso Giarratano, Diletta Favero, Laura Cortesi, Luca Moscetti, Mirco Pistelli, Rossana Berardi, Alberto Zambelli, Matteo Lambertini, Lucia Del Mastro, Valentina Guarneri, Claudio Vernieri, Giuseppe Curigliano,
Patients with breast cancer (BC) harbouring a germinal BRCA pathogenic variant (gBRCA-PV) may have an enhanced sensitivity to platinum-based chemotherapy (PBC) and PARP inhibitors (PARPi). As reported in ovarian cancer, however, sensitivity and resistance to these treatments could partially overlap. In patients with a gBRCA-PV and advanced BC (aBC), it remains unclear whether prior exposure to PARPi/PBC affects tumour response to subsequent PBC/PARPi, respectively.We conducted a retrospective, multicentric ...
Tópico(s): DNA Repair Mechanisms
2023 - Elsevier BV | European Journal of Cancer
Matteo Lambertini, Arlindo R. Ferreira, Lucia Del Mastro, Romano Danesi, P. Pronzato,
Introduction: Neutropenia and febrile neutropenia are the most common and most severe bone marrow toxicities of chemotherapy. Recombinant granulocyte-colony stimulating factors (G-CSFs), both daily (filgrastim and biosimilars, and lenograstim) and long-acting (pegfilgrastim and lipegfilgrastim) formulations, are currently available to counteract the negative consequences of these side effects.Areas covered: The purpose of this article is to review the physiopathology of chemotherapy-induced febrile ...
Tópico(s): Chemotherapy-related skin toxicity
2015 - Taylor & Francis | Expert Opinion on Biological Therapy
Matteo Lambertini, Lucia Del Mastro,
A possible side effect of anticancer treatments in premenopausal women is the occurrence of premature ovarian failure and subsequent infertility. The inheritance of a deleterious genetic mutation in the BRCA1 or 2 genes generates the hereditary breast and ovarian cancer syndrome. Additional fertility counseling for breast cancer patients with BRCA mutations is warranted to educate them about the available fertility preservation options in the context of their unique concerns (i.e., prophylactic gynecologic ...
Tópico(s): Ovarian function and disorders
2016 - Future Medicine | Breast Cancer Management
Lucia Lambertini, Giuseppe Coccarelli, Elisa Toto, M. Gabriella Santonicola, Susanna Laurenzi,
A C T Gels are soft materials composed of hydrophilic polymers cross-linked in water by physical or chemical bonds.Due to their lightweight and water-rich nature, these materials find application in various fields, including the space environment, for radiation protection purposes.In fact, thanks to their high hydrogen content, gels exhibit significant radiation stopping power, resulting in reduced fragmentation of incident particles.This suggests their potential utility in shielding electronic ...
Tópico(s): Polymer Nanocomposite Synthesis and Irradiation
2024 - Elsevier BV | Acta Astronautica
Matteo Lambertini, Eva Blondeaux, Francesco Perrone, Lucia Del Mastro,
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own ...
Tópico(s): Estrogen and related hormone effects
2019 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Antonio Andrea Grosso, Luca Lambertini, Fabrizio Di Maida, Maria Lucia Gallo, Andrea Mari, Andrea Minervini,
Purpose: Robot-assisted partial nephrectomy (RAPN) is rapidly increasing its role in the nephron-sparing surgery setting (1). The recent introduction of technological advancements is leading more experienced surgeons to approach complex renal mass with a conservative intent (2, 3). In particular, three-dimensional reconstruction and the use of intraoperative ultrasonography are gaining attention as crucial tools to safely and effectively approach complex cases (4, 5). We aimed to video-report the management ...
Tópico(s): Renal and related cancers
2022 - Sociedade Brasileira de Urologia | International braz j urol
Benedetta Conte, Luca Boni, Giancarlo Bisagni, Antonio Durando, Giovanni Sanna, Stefania Gori, Ornella Garrone, Stefano Tamberi, Sabino De Placido, Francesco Schettini, Antonio Pazzola, Riccardo Ponzone, Filippo Montemurro, Gianluigi Lunardi, Rosario Notaro, Maria De Angioletti, Anna Turletti, Mauro Mansutti, Fabio Puglisi, Antonio Frassoldati, Mauro Porpiglia, Alessandra Fabi, Daniele Generali, Giovanni Scognamiglio, Maura Rossi, Fara Brasó‐Maristany, Aleix Prat, Bárbara Cardinali, Patrizia Piccioli, Martina Serra, Sonia Lastraioli, Claudia Bighin, Francesca Poggio, Matteo Lambertini, Lucia Del Mastro,
Abstract Purpose: In estrogen receptor–positive (ER+) breast cancer, single-nucleotide polymorphisms (SNP) in the aromatase gene might affect aromatase inhibitors (AI) metabolism and efficacy. Here, we assessed the impact of SNP on prognosis and toxicity of patients receiving adjuvant letrozole. Experimental Design: We enrolled 886 postmenopausal patients in the study. They were treated with letrozole for 2 to 5 years after taking tamoxifen for 2 to 6 years, continuing until they completed 5 to 10 ...
Tópico(s): BRCA gene mutations in cancer
2023 - American Association for Cancer Research | Clinical Cancer Research
C. Bozza, Fabio Puglisi, Matteo Lambertini, Etin-Osa Osa, Massimo Manno, Lucia Del Mastro,
Breast cancer is the most common invasive cancer in women of reproductive age. In young women, chemotherapy may induce amenorrhea: it is still uncertain how to assess menopausal status in these patients despite the importance of its definition for choosing appropriate endocrine treatment. In the development of sensitive biomarkers for fertility and ovarian reserve, anti-Müllerian hormone (AMH) is considered a promising marker of ovarian reserve. The clearest data regarding a clinical use of AMH are ...
Tópico(s): Ovarian cancer diagnosis and treatment
2013 - Bioscientifica | Endocrine Related Cancer
Fabrizio Di Maida, Antonio Andrea Grosso, Riccardo Campi, Luca Lambertini, Maria Lucia Gallo, Anna Cadenar, Vincenzo Salamone, Simone Coco, Daniele Paganelli, Agostino Tuccio, Lorenzo Masieri, Andrea Minervini,
The role of redo partial nephrectomy (PN) for recurrent renal cell carcinoma (RCC) is still overlooked.To report our experience of salvage PN for local recurrence after previous nephron-sparing surgery (NSS).We prospectively gathered data from patients treated with robotic redo PN for locally recurrent RCC after previous NSS from January 2017 to January 2023. The type of surgical resection technique was assigned to the pathologic specimen according to the surface-intermediate-base (SIB) score.Redo PN ...
Tópico(s): Renal and related cancers
2023 - Elsevier BV | European Urology Open Science
Matteo Lambertini, Nermine S. Kamal, Fedro A. Peccatori, Lucia Del Mastro, Hatem A. Azim,
Introduction: The diagnosis of breast cancer during pregnancy (BCP) represents a unique challenge to the patient, her family and the treating physician. The proper management of this critical clinical situation is crucial, and requires a multidisciplinary approach. A proper understanding of the safety of chemotherapy during pregnancy is a vital step to avoid detrimental consequences on the mother and the fetus.Areas covered: The aim of this article is to review the available evidence on the safety ...
Tópico(s): Acute Lymphoblastic Leukemia research
2015 - Taylor & Francis | Expert Opinion on Drug Safety
Chiara Molinelli, Marco Bruzzone, Eva Blondeaux, Tommaso Ruelle, Chiara Lanzavecchia, Michelino De Laurentiis, Stefania Russo, Ferdinando Riccardi, Valentina Sini, Francesco Cognetti, Grazia Arpino, Alessandra Fabi, Palma Pugliese, Elena Collovà, Andrea Fontana, Fabio Puglisi, Claudia Bighin, Matteo Lambertini, Lucia Del Mastro,
Tópico(s): HER2/EGFR in Cancer Research
2024 - Elsevier BV | European Journal of Cancer
Lucia Del Mastro, Matteo Lambertini, Claudia Bighin, Alessia Levaggi, Alessia D’Alonzo, S. Giraudi, P. Pronzato,
Trastuzumab is a humanized monoclonal antibody against the extracellular domain of hEGF receptor-2 (HER2). Trastuzumab in combination with chemotherapy has proven efficacy in treating both early and metastatic HER2-positive breast cancer. In the metastatic setting, the addition of trastuzumab to chemotherapy is associated with a statistically significant longer time to disease progression, higher rate of objective response and improvement in overall survival. Trastuzumab efficacy is not influenced ...
Tópico(s): Peptidase Inhibition and Analysis
2012 - Taylor & Francis | Expert Review of Anticancer Therapy
Lucia Del Mastro, Matteo Lambertini,
Temporary ovarian suppression with gonadotropin-releasing hormone agonist during chemotherapy might be a reliable strategy not only to preserve ovarian function but also to increase the likelihood of becoming pregnant after the end of cytotoxic therapy. The findings of Blumenfeld et al. are consistent with recent data suggesting the efficacy of this strategy in preserving fertility.
Tópico(s): Cancer Risks and Factors
2015 - AlphaMed Press | The Oncologist
Barbara Buonomo, Antonella Brunello, S Noli, Loredana Miglietta, Lucia Del Mastro, Matteo Lambertini, Fedro A. Peccatori,
Tamoxifen is frequently used as adjuvant treatment in premenopausal patients with hormone receptor-positive early breast cancer. According to guidelines, the use of nonhormonal barrier contraception is recommended during tamoxifen treatment and up to 3 months after its interruption prior to attempting conception. Nevertheless, when conception occurs inadvertently during tamoxifen treatment, the effects on the fetus and on the course of pregnancy are still not completely known. Here, we report 3 ...
Tópico(s): Pregnancy and Medication Impact
2019 - Karger Publishers | Breast Care
Francesca Poggio, Marco Tagliamento, Chiara Pirrone, Davide Soldato, Benedetta Conte, Chiara Molinelli, Maurizio Cosso, Piero Fregatti, Lucia Del Mastro, Matteo Lambertini,
The diagnosis of breast cancer during pregnancy represents a challenging situation for the patient, her caregivers and physicians. Pregnancy adds complexity to oncological treatment planning, as many therapies can be potentially dangerous to the fetus. Therefore, a multidisciplinary approach is needed to offer a proper care for obtaining the best possible outcomes for the mother and the future child. Breast surgery is feasible throughout the pregnancy while radiotherapy should be postponed after ...
Tópico(s): Birth, Development, and Health
2020 - Multidisciplinary Digital Publishing Institute | Cancers
Francesca Poggio, Marco Tagliamento, Massimo Di Maïo, Valentino Martelli, Andrea De Maria, Emanuela Barisione, Marco Grosso, Francesco Boccardo, P. Pronzato, Lucia Del Mastro, Matteo Lambertini,
PURPOSE: To investigate the impact of the COVID-19 outbreak on the attitudes and practice of Italian oncologists toward breast cancer care and related research activities. METHODS: A 29-question anonymous online survey was sent by e-mail to members of the Italian Association of Medical Oncology and the Italian Breast Cancer Study Group on April 3, 2020. Only medical oncologists (both those in training and specialists) were invited to complete the questionnaire. RESULTS: Out of 165 responding oncologists, ...
Tópico(s): Global Cancer Incidence and Screening
2020 - Lippincott Williams & Wilkins | JCO Oncology Practice
Chiara Molinelli, Flavia Jacobs, Elisa Agostinetto, Guilherme Nader Marta, Marcello Ceppi, Marco Bruzzone, Eva Blondeaux, Francesco Schettini, Aleix Prat, Giuseppe Viale, Lucia Del Mastro, Matteo Lambertini, Evandro de Azambuja,
•Patients with HER2-low tumours showed better OS than those with HER2-zero cancers in both settings.•No differences were found in terms of PFS between patients with HER2-low and HER2-zero tumours.•Patients with HER2-low tumours showed a lower rate of pCR compared to those with HER2-zero cancers. BackgroundHuman epidermal growth factor receptor 2 (HER2)-low expression in breast cancer has been recently identified as a new therapeutic target. However, it is unclear if HER2-low status has an independent ...
Tópico(s): Monoclonal and Polyclonal Antibodies Research
2023 - Elsevier BV | ESMO Open